Worg’s vision for tomorrow’s AIT is to change the future of allergy treatment with the potential for both secondary and primary prevention due to the unique properties of the PCFiT platform which differentiates us from our competitors.

Secondary prevention

Prophylactic vaccination to prevent the transition from clinically silent IgE sensitization to the development of allergic symptoms. Children showing allergen-specific IgE reactivity are vaccinated in order to induce and maintain the production of blocking allergen-specific IgG antibodies to prevent the development of allergic symptoms.


Primary prevention

(A) Pre-natal vaccination of mothers should induce the basic production of allergen-specific blocking IgG antibodies which are then increased by a booster injection administered in the third trimester to transfer high levels of protective allergen-specific IgG to the child to prevent allergic sensitization postnatally. 

(B) Early post-natal prophylactic vaccination. Children receive early postnatal allergy vaccination to build up and maintain a protective allergen-specific IgG response to prevent allergic sensitization. Transfer of high maternal allergen-specific IgG antibody levels may protect the off-spring from becoming sensitized and developing allergen-specific IgE antibodies.